Similarly, it reviews proposals to improve treatment outcomes using image-based targeting, guidance, control, or potentiation of surgical treatments, including radiation, ultrasound, and light-based methods. Reviewed here are applications that use imaging as an active or intrinsic part of the treatment itself, as opposed to using imaging to identify targets for treatments which will be applied later. Applications may include substantial hardware, software, or computational development, and may be preclinical. However, all include studies that begin to evaluate the technology in the context of image-guided treatment.
The List of Reviewers lists all present, whether permanent or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.
The membership panel is a list of chartered members only.
- Theranostic agents; hardware and software of theranostic systems
- Imaging methods for monitoring therapies, including regenerative therapies
- Image-guided algorithms and systems, image registration, reconstruction, overlay, and display
- New image-guided surgical methods, including optical surgical navigation
- Image-guided drug delivery
- Precision medicine uses of imaging approaches
- Imaging-based histology, imaging-histology co-registration
Shared Interests and Overlaps
Imaging Probes and Contrast Agents [IPCA] also reviews applications proposing development of probes, tracers, or contrast agents. When the agent is proposed for purposes of actively guiding a therapeutic intervention, the work is likely to be reviewed in IGIS. Proposals for development of agents with more general application are usually reviewed in IPCA. Development of probes or tracers for diagnosis, or for use in basic biological research will be reviewed in IPCA.
Clinical Translational Imaging Science [CTIS] also reviews developmental imaging proposals with a translational emphasis. If the clinical translation is an image guided surgery or medical treatment the proposal will generally be reviewed in IGIS.
Emerging Imaging Technologies and Applications [EITA] also reviews proposals to refine protocols and optimize imaging systems for specific biological, physiological, and disease targets. If the goal of the optimization is use in an image-guided treatment, the proposal will likely be reviewed in IGIS.
Emerging Imaging Technologies in Neuroscience [EITN] reviews applications to develop biomedical imaging to address clinical/translational challenges in neurological disease. Generally, applications to develop an image guided surgical or medical treatment will be reviewed in IGIS, even if the target is a neurological disorder.
EImaging Technology Development [ITD] reviews grant applications to create new imaging technologies or to create new capabilities in existing modalities, often with the ultimate goal of solving a particular clinical problem. If the proposal includes clinical translational evaluation related to an image guided surgery or medical treatment, the proposal may be reviewed in IGIS.
Radiation Therapeutics and Biology [RTB] also reviews image guided therapy applications. Applications that focus on use of image guided therapies to targeting of radiation and assessment of response will be reviewed in RTB. Applications that focus on developing or evaluating new imaging technologies and protocols to target, guide, or control medical therapies, including chemotherapy, will be reviewed in IGIS.